InVivo Therapeutics Corpの価格/簿価
InVivo Therapeutics Corpの価格/簿価は何ですか。
InVivo Therapeutics Holdings Corpの価格/簿価は0.22です。
価格/簿価の定義は何ですか。
株価純資産倍率は、会社の株価と1株当たりの簿価との比率を表します。
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
NASDAQのセクタHealth Careにおける価格/簿価の企業と比べるInVivo Therapeutics Corp
InVivo Therapeutics Corpは何をしますか。
about invivo therapeutics invivo therapeutics holdings corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. the company was founded in 2005 with proprietary technology co-invented by robert langer, sc.d., professor at massachusetts institute of technology, and joseph p. vacanti, m.d., who then was at boston children’s hospital and who now is affiliated with massachusetts general hospital. in 2011, the company earned the david s. apple award from the american spinal injury association for its outstanding contribution to spinal cord injury medicine. in 2015, the company’s investigational neuro-spinal scaffold received the 2015 becker’s healthcare spine device award. the publicly-traded company is headquartered in cambridge, ma. for more details, visit www.invivotherapeutics.com. about the neuro-spinal scaffold™ following acute spinal cord injury, surgical implantation of the biodegradable neuro-spinal scaffold wi
InVivo Therapeutics Corpと類似の価格/簿価
- Sierra Metalsの価格/簿価は0.22です。
- Thor Mining Plcの価格/簿価は0.22です。
- Amazon.comの価格/簿価は0.22です。
- Voyager Digitalの価格/簿価は0.22です。
- Brand Architekts plcの価格/簿価は0.22です。
- Planet Venturesの価格/簿価は0.22です。
- InVivo Therapeutics Corpの価格/簿価は0.22です。
- TTL Beteiligungs- und Grundbesitz-AGの価格/簿価は0.22です。
- Hydoo Internationalの価格/簿価は0.22です。
- Tsakos Navigationの価格/簿価は0.22です。
- China Communications Construction Coの価格/簿価は0.22です。
- China Development Bank International Investmentの価格/簿価は0.22です。
- Integrated Waste Solutionsの価格/簿価は0.22です。